F11 and venous thromboembolism: Interest in targeting factor XI (FXI) as an anticoagulant strategy stems from observational data in humans showing that individuals with congenital FXI deficiency (haemophilia C) have only mild increase in bleeding in response to trauma and do not exhibit spontaneous bleeding events or increased risk of intracranial hemorrhage, but at the same time have a low incidence of stroke and venous thromboembolism (VTE) [7, 8].